Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Metrion Biosciences is a specialist ion channel contract research organisation providing drug discovery services to pharmaceutical and bioscience customers worldwide. Discover more about our capabilities and facilities in this short introductory video.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.